Neurent Medical

Neurent Medical

Private
IrelandHealthcare & Life Scienceshttps://neuromark.com/

Last Round

Series C

Feb 11, 2026

Total Funding Raised

$129.47M

Momentum Score

25 /100

Company Overview

Neurent Medical is a therapeutic devices company that provides NEUROMARK, a minimally invasive solution to treat chronic rhinitis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

chronic rhinitis treatmentradiofrequency ablationRF ablationENTotolaryngologyminimally invasive procedurein-office procedurenerve ablationimpedance-controlled RFmedical devicerhinologyrunny nose treatmentposterior nasal nervesPNNsingle-use deviceCPT code

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurent Medical Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neurent Medical Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 11, 2026
DebtDec 18, 2024
Series BJan 20, 2021
GrantJul 9, 2020
Series AMay 28, 2018

Key People

Founding team and executive leadership

David Townley

Co-Founder Chief Technology Officer

Founding Team

Declan Daly

Chief Financial Officer

Executive Team

Neurent Medical Investors

Notable investors and investment history

InvestorRounds
Atlantic Bridge CapitalSeries C, Series B, Series A
EQT Life SciencesSeries C, Series B
Claret Capital PartnersDebt
Western Development CommissionSeries A
Fountain Healthcare PartnersSeries C, Series B, Series A
EIT HealthGrant
Sofinnova PartnersSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 11, 2026

    $74M round led by MVM Life Science Partners.

Neurent Medical Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neurent Medical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neurent Medical's valuation, stock price, and market status.

Firmographic Details

HeadquartersIreland
Employee Range68
Year Founded2015
Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.